WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility
March 20 2018 - 08:00PM
Business Wire
WuXi Biologics (2269.HK), a leading global open-access biologics
technology platform company offering end-to-end solutions for
biologics discovery, development and manufacturing, today announced
that it has selected 4,000 liter (L) Custom Single Run (CSR®)
disposable bioreactors from ABEC for its new commercial
manufacturing facility (MFG4) in Wuxi city, Jiangsu, China. The
partnership followed WuXi Biologics’ successful testing and
evaluation of ABEC’s CSR bioreactor technology.
The 4,000L CSR is the largest single-use bioreactor size
available in the industry and potentially largest-ever design in
conventional disposable bioreactors, resulting in higher
productivity and significantly lowering the cost of goods for cell
culture-based biopharmaceuticals. The system also delivers
performance comparable to stainless steel systems of that scale and
can be fully customized for different products, resulting in higher
cell culture productivity and faster process transfer and scale-up.
With the scale-out strategy that WuXi Biologics pioneered in the
industry to use multiple disposable bioreactors for commercial
manufacturing, 4,000L CSRs will enable manufacturing up to the
scale of 24,000L comparable to traditional stainless steel
bioreactors yet still achieving the advantages of CAPEX and
timeline reduction benefited from disposables.
Dr. Chris Chen, CEO of WuXi Biologics, said, “We are proud to be
a global technology leader in bioprocessing and the first company
in Asia to advance this exciting new technology. ABEC’s large
volume single-use bioreactor greatly enhances our commercial
manufacturing potential by allowing not only scale-out of capacity
but also scale-up. In addition to the flexibility and time to
market benefits of single-use manufacturing, we can now offer our
clients true economies of scale and address biologics supply needs
from kilograms to tons.”
“WuXi Biologics’ successful testing, evaluation and investment
further validates ABEC’s CSR technology as one of the most flexible
single-use solutions available on the market,” said Scott
Pickering, ABEC President and CEO. “We are pleased to be part of
their next-generation manufacturing strategy, and look forward to
continuing this long-term partnership.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only
open-access biologics technology platform in the world offering
end-to-end solutions to empower organizations to discover develop
and manufacture biologics from concept to commercial manufacturing.
Our company history and achievements demonstrate our commitment to
providing a truly ONE-stop service offering and value proposition
to our global clients. For more information on WuXi Biologics,
please visit www.wuxibiologics.com.
About ABEC
Since 1974, ABEC has been a leader in delivering integrated
process solutions and services for manufacturing in the
biopharmaceutical industry. A majority of the world’s
pharmaceutical and biotech companies are ABEC customers with many
of today’s leading therapies manufactured by processes and
equipment engineered, manufactured, installed and serviced by ABEC.
ABEC’s unique value is based on long experience, complete in-house
capabilities, a custom, flexible approach, and long-term
credibility. Whether adding capacity or improving existing
facilities ABEC’s turn-key solutions and support services reduce
overall cost and time to market while delivering maximum
productivity. www.abecsingleuse.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180320006567/en/
WuXi BiologicsJia Li,
+86-21-2066-4528li_jia0102@wuxiapptec.comorABECSusan Cooper
Curcio, +1 610-861-4666scurcio@abec.com